Abstract: AIM: To compare the therapeutic effect of paclitaxel containing platinum (cisplatin or carboplatin) and cyclophosphamide containing platinum chemotherapy in women with epithelial ovarian cancer.METHODS: 24 cases with advanced epithelial ovarian cancer after initial surgery received paclitaxel and cisplatin or carboplati.Paclitaxel (135 mg·m^-2, over a period of 3 hours) was administered iv once every 3 to 4 weeks, in comparison with those 30 cases treated with “CAP ” or “CVP” regimen.RESULTS: The overall median survival time was significantly longer in the paclitaxel-platinum group than that in the cisplatin-cyclophosphamide group (median 41.5 vs 32.6 mon, P <0.01).Among 24 women with measurable disease, 75 percents in the “TP” group responded to the therapy, comparing with 40 percent in the “CP” group (P <0.05).CONCLUSION: Paclitaxel and platinum agent is more effective than “CP” regimen in the treatment of patients with advanced epithelial ovarian cancer.

Key words: ovarian neoplasms, paclitaxel, cisplatin, carboplatin, chemotherapy